In MM cells, the concurrent use of the NEK2 inhibitor INH1 and P5091 markedly impedes cell growth and overcomes NEK2-related and inherent BTZ resistance by modulating the NF-κB and PP1α/AKT pathways [175]. This evidence concerns the gene CASC3 and Miyoshi myopathy.